Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction
- PMID: 33342227
- PMCID: PMC7955468
- DOI: 10.1161/JAHA.119.016215
Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction
Abstract
Background Evidence-based medication adherence rates after a myocardial infarction are low. We hypothesized that 90-day prescriptions are underused and may lead to higher evidence-based medication adherence compared with 30-day fills. Methods and Results We examined patients with myocardial infarction treated with percutaneous coronary intervention between 2011 and 2015 in the National Cardiovascular Data Registry. Linking to Symphony Health pharmacy data, we described the prevalence of patients filling 30-day versus 90-day prescriptions of statins, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and P2Y12 inhibitors after discharge. We compared 12-month medication adherence rates by evidence-based medication class and prescription days' supply and rates of medication switches and dosing changes. Among 353 259 patients with myocardial infarction treated with percutaneous coronary intervention, 90-day evidence-based medication fill rates were low: 13.0% (statins), 12.3% (β-blockers), 14.6% (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers), and 9.7% (P2Y12 inhibitors). Patients filling 90-day prescriptions were more likely older (median 69 versus 62 years) with a history of prior myocardial infarction (25.0% versus 17.9%) or percutaneous coronary intervention (30.3% versus 19.5%; P<0.01 for all) than patients filling 30-day prescriptions. The 12-month adherence rates were higher for patients who filled 90-day versus 30-day supplies: statins, 83.1% versus 75.3%; β-blockers, 72.7% versus 62.9%; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 71.1% versus 60.9%; and P2Y12 inhibitors, 78.5% versus 66.6% (P<0.01 for all). Medication switches and dosing changes within 12 months were infrequent for patients filling 30-day prescriptions-14.7% and 0.3% for 30-day P2Y12 inhibitor fills versus 6.3% and 0.2% for 90-day fills, respectively. Conclusions Patients who filled 90-day prescriptions had higher adherence and infrequent medication changes within 1 year after discharge. Ninety-day prescription strategies should be encouraged to improve post-myocardial infarction medication adherence.
Keywords: adherence; evidence‐based medications; myocardial infarction.
Conflict of interest statement
Dr Rymer reports research grant support from Boston Scientific and Abbott Pharmaceuticals. E. Fonseca was a full‐time employee and shareholder of AstraZeneca during the study conduct. D.D. Bhandary and D. Kumar are full‐time employees of AstraZeneca. Dr Khan is a full‐time employee of AstraZeneca. Dr Wang reports research grant support from AstraZeneca, Boston Scientific, CryoLife, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, and Regeneron as well as educational support from AstraZeneca, Bristol Myers Squibb, Gilead, and Merck and consulting from Pfizer and Sanofi‐Aventis.
Figures


Similar articles
-
Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005455. doi: 10.1161/CIRCOUTCOMES.118.005455. Epub 2019 Oct 31. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31665896
-
Long-term medication adherence in patients with ST-elevation myocardial infarction and primary percutaneous coronary intervention.Eur J Prev Cardiol. 2015 Jul;22(7):890-8. doi: 10.1177/2047487314540385. Epub 2014 Jun 17. Eur J Prev Cardiol. 2015. PMID: 24938277
-
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783. JAMA Intern Med. 2018. PMID: 29799992 Free PMC article.
-
Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2020 Jun 2;9(11):e014742. doi: 10.1161/JAHA.119.014742. Epub 2020 May 20. J Am Heart Assoc. 2020. PMID: 32431190 Free PMC article.
-
The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.Eur J Prev Cardiol. 2017 Jun;24(9):962-970. doi: 10.1177/2047487317695628. Epub 2017 Jan 1. Eur J Prev Cardiol. 2017. PMID: 28436725 Review.
Cited by
-
Improving medication adherence in cardiovascular disease.Nat Rev Cardiol. 2024 Jun;21(6):417-429. doi: 10.1038/s41569-023-00972-1. Epub 2024 Jan 3. Nat Rev Cardiol. 2024. PMID: 38172243 Review.
-
Patients' Experiences with Refilling their HIV Medicines: Facilitators and Barriers to On-Time Refills.Perm J. 2020 Dec;24:1-3. doi: 10.7812/TPP/19.207. Perm J. 2020. PMID: 33482953 Free PMC article.
-
Change in Default Prescription Length and Statin Prescribing Behavior.JAMA Intern Med. 2025 Jun 1;185(6):736-739. doi: 10.1001/jamainternmed.2025.0185. JAMA Intern Med. 2025. PMID: 40193086 Free PMC article.
-
Medication Adherence in Medicare-Enrolled Older Adults with Chronic Obstructive Pulmonary Disease before and during the COVID-19 Pandemic.J Clin Med. 2022 Nov 26;11(23):6985. doi: 10.3390/jcm11236985. J Clin Med. 2022. PMID: 36498558 Free PMC article.
-
Evaluation of a Novel Pharmacist-Delivered Adherence Improvement Service via Telehealth.Pharmacy (Basel). 2021 Aug 17;9(3):140. doi: 10.3390/pharmacy9030140. Pharmacy (Basel). 2021. PMID: 34449707 Free PMC article.
References
-
- Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation. 2011;124:2458–2473. - PubMed
-
- Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug‐eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809. - PubMed
-
- Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–1036. - PubMed
-
- Choudhry NK, Glynn RJ, Avorn J, Lee JL, Brennan TA, Reisman L, Toscano M, Levin R, Matlin OS, Antman EM, et al. Untangling the relationship between medication adherence and post‐myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014;167:51–58. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical